Discovery US 2024

07 - 08 November 2024 | Boston, MA

Connecting experts in biology & chemistry to advance small molecule drug discovery

Event Page - Hero Banner 6

Explore Discovery US 2024: Fast-Tracking Novel Target Identification & Validation

As recent technological and pharmacological advances tackle the previously ‘undruggable’, Discovery US returns to support the discovery of novel pharmaceutical modalities beyond the rule of five – including novel degraders, molecular glues, orally-available peptides and radioligands.

The focussed, two-day agenda showcases the key platforms and technologies impacting early drug pipelines, from DNA-encoded libraries and phenotypic screening through to AI algorithms and organoid models. It brings together experts in target discovery and validation from across small & large biopharma organizations to discuss how the newest therapeutic paradigms can overcome historic challenges in drug development and provide optimized, novel drug candidates. Further sessions explore the use of automation to augment drug development and improve your lab productivity, showcasing the competitive advantages that can be gained in drug development through digitalization and robotics.

Discovery US 2024

  • Benefit from our revamped programme for 2024, designed to provide in-depth discussion of the key technologies, modalities & platforms transforming small molecule drug discovery  
  • Discover emerging drug targets beyond the rule of five, from Induced Proximity & Molecular Glues through to siRNAs and orally-available peptides, with case studies on the chemical & biological considerations of developing these complex molecules
  • Enable your lab to operate at peak productivity. Maximize your R&D capabilities with integration of advanced robotics & automation, as well as utilizing AI to augment your drug development

Agenda at a Glance


  • Day One | Track 1: Target Identification & Validation of Novel Modalities
  • Day One | Track 2: Novel Models For ADME-Tox Research & Disease Modelling 
  • Day One | Track 3: Augmenting R&D With AI and Automation
  • Day Two | Track 1: Innovative Technologies For Hit Identification & Screening
  • Day Two | Track 2: Computational & Medicinal Chemistry

What to Expect

300

leading pharma, biotech & academic delegates

40
hours of presentations, discussions & interactive content
11
hours of networking breaks, including speed networking & refreshments
57
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 75 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Meet Our Expert Speakers

Discovery US 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Abhijat Vatsyayan
Head of Artificial Intelligence,
Taiho Oncology
Divya Kanichar
Director,
Insitro
Fiona Mack
Vice President, Head, Bayer Co.Lab Cambridge,
Bayer
Giovanni Piedimonte
Vice President of Research,
Tulane University
Graham Dempsey
Founder & Chief Scientific Officer,
Quiver Bioscience
Hong Cheng
Vice President, Head of Research Strategy,
Sanofi
Jason Ekert
Head,
UCB
Jennifer Busby
Director Biology,
Exscientia
Julie Owen
Director,
Recursion Pharmaceuticals
Martin Redhead
Assistant Vice President,
Exscientia
Paul Scola
Senior Director,
Bristol Myers Squibb
Shelley Allen
Vice President, Head of Drug Discovery,
Nimble Therapeutics
Aaron Van Hooser
Senior Director, Computational Biology,
Sensorium Therapeutics
Anneke den Hollander
Head of Cellular Genomics,
AbbVie
Ari Allyn-Feuer
Director,
GSK
Boguslaw Nocek
Senior Director,
Eli Lilly
Christopher Hickey
Associate Director,
Arvinas
Dima Kozakov
Professor,
The Laufer Center
Elizabeth D'Ambrosio
Investigator, ELT,
GSK
Finith Jernigan
Head of Early Discovery,
Psivant
Gvido Cebers
Global Head of Drug Safety, Research & Evaluation,
Takeda Pharmaceuticals
Ilkay Us
Director, High Throughput Screening,
Cornell University
Ivan Cornella
CSO,
Covant Therapeutics
James Hickman
Professor of NanoScience Technology,
University of Central Florida
Jeremy Disch
Senior Director,
Insitro
Jody Logan
Senior Director of Tech Transfer,
Genentech
Joe Franklin
Senior Vice President and Head of Early Discovery,
Anagenex
Jonathan Solomon
Director,
Novartis Pharma
Joseph Wu
Director, Stanford Cardiovascular Institute; Co-Founder, Greenstone Biosciences,
Stanford University
Judith Ronau
Senior Scientist,
AbbVie
Julia Fox
Director, Data & Analytics,
Takeda
Kian Tan
Director,
Novartis
Kristen Marino
Principal Scientist, Computational Chemistry,
Cellarity
Lena Dolgikh
Head of CADD,
Monte Rosa Therapeutics
Melissa Ford
Associate Director,
Kymera Therapeutics
Michael Brehm
Associate Professor & Associate Director, Diabetes Center of Excellence,
University of Massachusetts Medical School
Monica Wang
Senior Scientist,
UCB
Nicholas Larsen
Senior Director of Biophysics and Structural Biology,
Kestrel Therapeutics
Noa Liberman-Isakov
Senior Scientist,
Sarepta Therapeutics
Noel Powell
Senior Director -Medicinal Chemistry,
Recursion Pharmaceuticals
Prashant Gahtori
Professor,
Graphic Era Hill University
Rick Ewing
Vice President, Head of Chemistry,
Rapafusyn Pharmaceuticals
Ron Weiss
Professor,
Massachusetts Institute of Technology
Sarah Wilson
Principal Research Scientist,
AbbVie
Satyajit Rajapurkar
Investigator,
GSK
Tudor Oprea
CEO,
Expert Systems
Yuan Wang
Head, Research Analytics,
UCB
Yunhui Ge
Scientist,
Alkermes

Interested in Sponsoring?

Our extensive and engaged community extends across large, mid-size and emerging companies within the pharma and biotech space, with a dedicated audience spanning a range of specialisms. Whether you have content to share, are looking for ways to enhance your brand visibility or would like to increase engagement with prospective customers, Oxford Global can offer valuable access to your target demographic through our range of event & content services.

Latest Resources

2024 Nobel Prize in Chemistry Awarded to Pioneering Advances in Protein Design and Structure Prediction

The 2024 Nobel Prize in Chemistry was awarded to three scientists working on computational protein design and protein structure prediction.

Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years

According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults.

The Power of Philanthropy in Transforming Pancreatic Cancer Research

The Stephenson Prize for innovation in pancreatic cancer research was launched alongside a $150 million gift to City of Hope.

The Role of Immuno-Organoids in Drug Discovery And Disease Modelling

A study conducted by Roche demonstrates how to create new human models with tissue-integrated immune cells.

Strategic Acquisition: Otsuka Pharmaceutical to Pay Up to $1.1 billion to Acquire Jnana Therapeutics' Drug Discovery Platform

The Japanese healthcare company Otsuka Pharmaceutical will acquire clinical-stage biotech Jnana Therapeutics.

Exscientia and Amazon Web Services Join Forces to Maximise the Potential Of Generative AI in Drug Discovery

Exscientia, a biotech and pioneer in technology-driven drug design, has teamed up with Amazon Web Services to bolster its AI drug discovery platform.

Plan Your Visit

Boston Marriott Cambridge
50 Broadway, Cambridge, MA 02142, United States

Public Transportation:

The nearest Bus station is South Station
The nearest Subway station is Kendall/MIT
The nearest Train stations are North Station and South Station
For more information, please click here.

 

By Air: 

Boston Logan International Airport is the nearest airport to the venue – 5 miles from the property. 
For more information, please call +1 800-2356426 or click here.

 

Parking:

On site valet parking: $58.99 (valet with in/out privileges)
Off site self-parking: $48.00 daily (no in/out privileges)

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery US 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch